BRAF mutation has been proven to predict the efficacy of targeted drugs in the treatment of colorectal cancer and is an independent negative factor affecting the clinical efficacy of bevacizumab added to chemotherapy [23, 24]. This evidence concerns the gene BRAF and colorectal cancer.